225Ac-EBTATE / Molecular Targeting Tech - LARVOL DELTA

MTTI ²²⁵Ac-EBTATE is Highly Effective Against Neuroendocrine Tumors (Businesswire) - "Molecular Targeting Technologies, Inc. (MTTI) published preclinical study results for their proprietary ²²⁵Ac-EBTATE against SSTR2 NET cancers online in the European Journal of Nuclear Medicine....'At just 40% of the administered dose reported for ²²⁵Ac-DOTATATE, ²²⁵Ac-EBTATE produces enhanced anti-tumor efficacy in Small Cell lung cancer (SCLC) and Pan-neuroendocrine tumor (NET) models as shown with complete tumor remissions. At a therapeutic dose of 2x 34 kBq, ²²⁵Ac-EBTATE showed general safety for 28 days after blood biochemistry analysis, CBC, and histopathological examination of major organs and tissues. We demonstrated that 225Ac-EBTATE was effective against human small-cell lung cancer (SCLC) with 80% complete remission and 100% survival in preclinical models'."

Preclinical • Neuroendocrine Tumor • Small Cell Lung Cancer